Page last updated: 2024-09-04

irofulven and Vomiting

irofulven has been researched along with Vomiting in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ	1
Baker, SD; Britten, CD; Clark, GM; Drengler, R; Eckhardt, SG; Felton, S; Hammond, LA; Hidalgo, M; Kuhn, JG; MacDonald, JR; Moczygemba, J; Rowinsky, EK; Siu, L; Smith, C; Smith, SL; Villalona-Calero, MA; Von Hoff, DD; Weitman, S	1
DeVore, RF; Dowell, JE; Johnson, DH; Krozely, P; McCullough, N; Rogers, JS; Shyr, Y	1
Alberti, D; Arzoomanian, R; Bailey, H; Binger, K; Feierabend, C; MacDonald, J; Marnocha, R; Smith, C; Smith, S; Steele, T; Thomas, JP; Tutsch, KD; Wilding, G	1

Trials

3 trial(s) available for irofulven and Vomiting

Article	Year
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting	2004
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. Investigational new drugs, 2001, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Sesquiterpenes; Thrombocytopenia; Toxicity Tests; Treatment Outcome; Vomiting	2001
Phase I clinical and pharmacokinetic trial of irofulven. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6 Topics: Acidosis; Aged; Anorexia; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Sesquiterpenes; Vomiting	2001

Other Studies

1 other study(ies) available for irofulven and Vomiting

Article	Year
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting	2000

Article

Year

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting

2000